Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Takeda

- PMLiVE

Governments continue proposed pandemic agreement progress ahead of World Health Assembly

The meeting focusing on ‘All for Health, Health for All’ takes place on 27 May to 7 June 2024

- PMLiVE

Takeda’s Qdenga becomes second dengue vaccine to receive WHO prequalification

Approximately half of the global population is at risk of mosquito-borne viral disease

- PMLiVE

Takeda gains exclusive option for AC Immune’s Alzheimer’s drug candidate in deal worth over $2.1bn

The agreement includes an option to licence global rights to the anti-amyloid beta immunotherapy

- PMLiVE

WHO opens application period for 2025 Model Lists of Essential Medicines

The deadline to submit ahead of the 25th WHO Expert Committee meeting is 1 November 2024

- PMLiVE

Takeda’s fruquintinib recommended by CHMP for metastatic colorectal cancer

Approximately 520,000 new cases of colorectal cancer were diagnosed in Europe in 2020

- PMLiVE

WHO reveals ‘extensive’ worldwide overuse of antibiotics during COVID-19 pandemic

Findings from the report reveal factors that could have contributed to the spread of antimicrobial resistance

- PMLiVE

Takeda’s subcutaneous Entyvio approved by FDA as Crohn’s disease maintenance therapy

Inflammatory bowel disease affects around ten million people worldwide

- PMLiVE

World Health Organization prequalifies simplified oral cholera vaccine Euvichol-S

The acute diarrhoeal illness was reported to affect around 473,000 people in 2022

- PMLiVE

Takeda gains rights to Kumquat’s immune-oncology programme in deal worth over $1.2bn

The selected candidate can be developed as a monotherapy, combination therapy or both

- PMLiVE

Takeda’s Takhzyro granted MHRA approval for younger hereditary angioedema patients

The rare genetic disorder is estimated to affect one in every 50,000 people

- PMLiVE

World Health Organization launches AI-powered digital health assistant for public health

SARAH has been launched in alignment with World Health Day’s theme, ‘My Health, My Right’

- PMLiVE

Takeda’s HyQvia receives MHRA approval for rare neurological disorder CIDP

The therapy offers patients with CIDP a typical dosing interval of four weeks

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links